Real-world efficacy and safety of open-source automated insulin delivery for people with type 1 diabetes mellitus: Experience from mainland China
Authors' conclusion
Real-world data from mainland China highlights current uptake of open-source AAPS with potential glycemic benefits. No safety signals are seen. More support to enhance access and utilization of all AID systems in this region is warranted.
Study context
- Population
- People with T1D in mainland China who initiated android artificial pancreas (AAPS) for ≥3 months between 2019 and 2024; aged 25.7 (14.7, 35.0) years, 46.9% male183 at 6 and 68 at 12 months
- Participants
- 292 people
- Exposure
- Hemoglobin A1c (HbA1c) and CGM metrics before vs after initiation of open-source AAPS
- Outcome
- HbA1c
- Follow-up
- 3 months
Main finding
As reported in the abstract
| Group | Value | HbA1c <7.0% |
|---|---|---|
| AAPS | mean 6.3 ± 0.8 % | 82.9% |
AAPS
Valuemean 6.3 ± 0.8 %
HbA1c <7.0%82.9%
- Mean HbA1c change from prior-AAPS (P < 0.01)
- −1.5 ± 2.0 %
Observational data: associations, not effects.
Further findings
HbA1c before AAPS · baseline
- Prior-AAPS HbA1c, mean ± SD
- 7.6 ± 1.7 %
- Achieving HbA1c < 7.0 % before AAPS
- 44.5 %
TIR 3.9-10.0 mmol/L · 3 months
- TIR improved to, mean ± SD
- 78.8 ± 12.9 %
- Achieving TIR > 70 %
- 80.5 %
- Time below 3.9 mmol/L, median (IQR)
- 3.9 (2.1, 6.1) %
HbA1c < 7.0 % · 3 months
- Achieving HbA1c < 7.0 %
- 82.9 %
HbA1c and TIR · 12 months
- HbA1c remained similar, mean ± SD
- 6.4 ± 1.0 %
- TIR remained similar, mean ± SD
- 77.9 ± 12.2 %
Safety
- No diabetic ketoacidosis (DKA) and severe hypoglycemia was observed
Original publication
Real-world efficacy and safety of open-source automated insulin delivery for people with type 1 diabetes mellitus: Experience from mainland China. Diabetes Res Clin Pract. Published 30 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →